project . 2011 - 2013 . Closed

Therapeutic potential of human apurinic/apyrimidinic endonuclease 1 (APE1) modulation in melanoma

UK Research and Innovation
  • Funder: UK Research and InnovationProject code: G1000252
  • Funded under: MRC Funder Contribution: 192,108 GBP
  • Status: Closed
  • Start Date
    01 Jan 2011
    End Date
    31 Dec 2013
Description
Chemotherapy and radiation therapy are commonly used to treat melanoma. However many melanomas are resistant to such treatments because the cancer cells are able to counteract the effects of therapy by utilising the DNA repair machinery to repair DNA damage induced by these agents. The focus of my research is to develop drugs to block DNA repair in cells and thereby enhance cancer cell death. This will lead to better response to treatments and improve patient outcomes. My research will focus on APE1, an essential protein involved in DNA base excision repair. The host laboratory has developed compounds that can inhibit APE1 and I will evaluate the effects of thes...
Partners
Description
Chemotherapy and radiation therapy are commonly used to treat melanoma. However many melanomas are resistant to such treatments because the cancer cells are able to counteract the effects of therapy by utilising the DNA repair machinery to repair DNA damage induced by these agents. The focus of my research is to develop drugs to block DNA repair in cells and thereby enhance cancer cell death. This will lead to better response to treatments and improve patient outcomes. My research will focus on APE1, an essential protein involved in DNA base excision repair. The host laboratory has developed compounds that can inhibit APE1 and I will evaluate the effects of thes...
Partners
Any information missing or wrong?Report an Issue